Literature DB >> 36178700

Human Monkeypox Virus Infection in the Immediate Period After Receiving Modified Vaccinia Ankara Vaccine.

Aniruddha Hazra1, Laura Rusie1, Trevor Hedberg1, John A Schneider1.   

Abstract

Entities:  

Year:  2022        PMID： 36178700      PMCID： PMC9526114          DOI： 10.1001/jama.2022.18320

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   157.335


× No keyword cloud information.
  3 in total

1.  Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.

Authors:  Phillip R Pittman; Matthew Hahn; HeeChoon S Lee; Craig Koca; Nathaly Samy; Darja Schmidt; Joachim Hornung; Heinz Weidenthaler; Christopher R Heery; Thomas P H Meyer; Günter Silbernagl; Jane Maclennan; Paul Chaplin
Journal:  N Engl J Med       Date:  2019-11-14       Impact factor: 91.245

2.  Update on the Monkeypox Outbreak.

Authors:  Carlos Del Rio; Preeti N Malani
Journal:  JAMA       Date:  2022-09-13       Impact factor: 157.335

3.  Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.

Authors:  Edgar Turner Overton; Jack Stapleton; Ian Frank; Shawn Hassler; Paul A Goepfert; David Barker; Eva Wagner; Alfred von Krempelhuber; Garth Virgin; Thomas Peter Meyer; Jutta Müller; Nicole Bädeker; Robert Grünert; Philip Young; Siegfried Rösch; Jane Maclennan; Nathaly Arndtz-Wiedemann; Paul Chaplin
Journal:  Open Forum Infect Dis       Date:  2015-05-05       Impact factor: 3.835
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.